Almost nine months of talks gave birth to the potential $1 billion deal disclosed Monday morning by MacroGenics Inc., which will deploy the company's Dual‐Affinity Re‐Targeting (DART) technology for drugs directed at up to four targets in an agreement with Gilead Sciences Inc.